5nda
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | The | + | ==NMR Structural Characterisation of Pharmaceutically Relevant Proteins Obtained Through a Novel Recombinant Production: The Case of The Pulmonary Surfactant Polypeptide C Analogue rSP-C33Leu.== |
+ | <StructureSection load='5nda' size='340' side='right' caption='[[5nda]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[5nda]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5NDA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5NDA FirstGlance]. <br> | ||
+ | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5nda FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5nda OCA], [http://pdbe.org/5nda PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5nda RCSB], [http://www.ebi.ac.uk/pdbsum/5nda PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5nda ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Membrane proteins are targets of most available pharmaceuticals, but they are difficult to produce recombinantly, like many other aggregation-prone proteins. Spiders can produce silk proteins at huge concentrations by sequestering their aggregation-prone regions in micellar structures, where the very soluble N-terminal domain (NT) forms the shell. We hypothesize that fusion to NT could similarly solubilize non-spidroin proteins, and design a charge-reversed mutant (NT*) that is pH insensitive, stabilized and hypersoluble compared to wild-type NT. NT*-transmembrane protein fusions yield up to eight times more of soluble protein in Escherichia coli than fusions with several conventional tags. NT* enables transmembrane peptide purification to homogeneity without chromatography and manufacture of low-cost synthetic lung surfactant that works in an animal model of respiratory disease. NT* also allows efficient expression and purification of non-transmembrane proteins, which are otherwise refractory to recombinant production, and offers a new tool for reluctant proteins in general. | ||
- | + | Efficient protein production inspired by how spiders make silk.,Kronqvist N, Sarr M, Lindqvist A, Nordling K, Otikovs M, Venturi L, Pioselli B, Purhonen P, Landreh M, Biverstal H, Toleikis Z, Sjoberg L, Robinson CV, Pelizzi N, Jornvall H, Hebert H, Jaudzems K, Curstedt T, Rising A, Johansson J Nat Commun. 2017 May 23;8:15504. doi: 10.1038/ncomms15504. PMID:28534479<ref>PMID:28534479</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
+ | <div class="pdbe-citations 5nda" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
[[Category: Johansson, J]] | [[Category: Johansson, J]] | ||
- | [[Category: Pioselli, B]] | ||
[[Category: Kronqvist, N]] | [[Category: Kronqvist, N]] | ||
[[Category: Nordling, K]] | [[Category: Nordling, K]] | ||
+ | [[Category: Pioselli, B]] | ||
[[Category: Rising, A]] | [[Category: Rising, A]] | ||
[[Category: Venturi, L]] | [[Category: Venturi, L]] | ||
+ | [[Category: Fusion protein]] | ||
+ | [[Category: Nt domain]] | ||
+ | [[Category: Protein]] | ||
+ | [[Category: Protein structure]] | ||
+ | [[Category: Pulmonary surfactant protein]] | ||
+ | [[Category: Recombinant protein]] | ||
+ | [[Category: Solubility tag]] | ||
+ | [[Category: Sp-c analogue]] |
Revision as of 10:53, 13 September 2017
NMR Structural Characterisation of Pharmaceutically Relevant Proteins Obtained Through a Novel Recombinant Production: The Case of The Pulmonary Surfactant Polypeptide C Analogue rSP-C33Leu.
|